Clinical trial
A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects
NCT00538174 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects
- Lead sponsor
- AstraZeneca
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2007
- Completion date
- May 31, 2008
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.